Radiopharmaceuticals market seen reaching $18.52 billion by 2035

The global radiopharmaceuticals market is projected to grow from $7.74 billion in 2025 to $18.52 billion by 2035, driven by rising cancer and cardiovascular disease rates, theranostics adoption and expanding nuclear medicine infrastructure. North America leads the market now, while Asia-Pacific is expected to grow fastest.

Why it matters: - Radiopharmaceuticals are becoming a bigger part of cancer, heart disease and neurodegenerative disease care. - The market's projected rise signals stronger demand for targeted diagnosis and localized treatment with less damage to healthy tissue. - Growth could widen access to PET and SPECT imaging, radioligand therapies and theranostic care across hospitals and specialty centers.

What happened: - Market Research Future said the global radiopharmaceuticals market was valued at $7.09 billion in 2024. - The firm projected the market will grow to $7.74 billion in 2025 and reach $18.52 billion by 2035. - The forecast implies a 9.12% CAGR from 2025 to 2035. - The release was dated Aug. 24, 2026.

The details: - Cancer, cardiovascular disease and neurodegenerative disease are fueling demand for nuclear medicine tools. - Theranostics is driving interest by pairing diagnostic imaging with targeted radionuclide therapy. - Diagnostic isotopes such as Gallium-68 and Fluorine-18 are used to visualize targets before therapeutic isotopes like Lutetium-177 and Actinium-225 are given. - High-yield medical cyclotrons, automated synthesis modules and generator platforms are improving isotope production and distribution. - Targeted alpha therapies are gaining attention because of their localized cell-killing capability. - Radiopharmaceutical use is expanding beyond oncology into Alzheimer's diagnosis and myocardial perfusion imaging. - Diagnosis held about 64% market share in 2024. - Therapy is the fastest-growing application segment through 2035. - Diagnostic radiopharmaceuticals led the market by type, supported by PET/CT scans, Technetium-99m agents and Fluorine-18 tracers. - Therapeutic radiopharmaceuticals are growing on demand for radioimmunotherapies, beta-emitters and alpha-emitters. - Hospitals remained the dominant end-use segment. - Diagnostic imaging centers are expanding fast as outpatient access to PET/CT and SPECT grows.

Between the lines: - The market shift reflects a broader move toward precision medicine and earlier nuclear imaging in treatment paths. - Supply chain reliability remains a major commercial issue because many isotopes have short half-lives. - Centralized radiopharmacy networks and isotope producer partnerships are helping ease logistics constraints. - Reimbursement updates in North America and supportive European regulation are improving access for new drugs. - North America led the market in 2024 with more than 45.13% share and about $3.20 billion in revenue. - Asia-Pacific is the fastest-growing region as China, India, Japan and South Korea expand nuclear medicine capacity. - China is projected to grow from $0.53 billion in 2024 to $1.28 billion by 2035. - South Korea is projected to grow from $1.25 billion in 2024 to $3.50 billion by 2035. - Europe remains a major market with established infrastructure and manufacturing capacity. - South America and the Middle East & Africa are emerging markets tied to healthcare modernization.

What's next: - The release expects targeted alpha therapies using Actinium-225 and Lead-212 to become more commercial by 2035. - AI-driven radiomics and automated PET analysis are expected to improve diagnostic precision and dose planning. - Decentralized isotope generators and compact cyclotron networks could expand access outside major medical hubs. - Market competition will likely center on isotope supply, radioligand platforms and distribution networks. - The release identified Novartis, GE Healthcare, Siemens Healthineers, Bayer, Cardinal Health, Curium Pharma, Elekta, Lantheus, Bracco Imaging and Telix Pharmaceuticals as major participants. - A free sample, customization request and full report are available through Market Research Future's links: Request a free sample, Ask for customization, Read detailed insights.

The bottom line: - Radiopharmaceuticals are moving from a niche imaging field to a broader precision-medicine platform, with the strongest growth coming from targeted therapies and expanding global imaging infrastructure.